Biogen Alzheimer’s Drug Accepted for EMA PRIME

03.06.2016 - Biogen’s investigational treatment for early Alzheimer’s disease (AD), aducanumab, has been accepted into the European Medicines Agency’s (EMA) PRIority MEdicines (PRIME) program...